LifeMD (LFMD) News Today

LifeMD, Inc. (NASDAQ: LFMD) faced mixed analyst revisions, with the overall tone skewing negative as HC Wainwright lowered several earnings forecasts. The stock has decreased as investors weigh continued losses and weaker near-term expectations against the firm’s retained bullish rating.

• Positive Sentiment: HC Wainwright maintained its Buy rating and $9.00 price target, well above recent trading levels, suggesting substantial upside if LifeMD executes on its longer-term growth plans. The firm raised its Q4 2026 EPS forecast to $0.06 from $0.02, FY2026 EPS to $(0.46) from $(0.47), Q1 2027 EPS to $(0.07) from $(0.09), and Q4 2027 EPS to $0.17 from $0.15. LifeMD analyst estimates
• Neutral Sentiment: The revisions imply a choppy path to profitability. HC Wainwright projects a $(0.46) loss for FY2026 and a $(0.12) loss for FY2027, although it expects LifeMD to produce positive earnings in Q4 2026 and Q4 2027.
• Negative Sentiment: The analyst cut its Q3 2026 EPS estimate to $(0.15) from $(0.05), Q2 2027 to $(0.13) from $(0.12), Q3 2027 to $(0.09) from $0.06, and FY2027 to $(0.12) from $(0.01). The FY2027 reduction is particularly significant because it indicates profitability may arrive more slowly than previously expected.
• Negative Sentiment: LifeMD’s latest quarterly results also showed modest pressure, with EPS of $(0.16) missing the $(0.15) consensus estimate and revenue of $47.28 million below the $49.16 million forecast. The company remains unprofitable, increasing investor sensitivity to downward estimate changes.